Rona Therapeutics

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1/2
APOC3RNA / oligonucleotide
Cardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Phase 1
PCSK9RNA / oligonucleotide
Atherosclerotic Cardiovascular Disease
Phase 1
PCSK9 and LPA (bivalent, dual-target)RNA / oligonucleotide
Atherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.